Cancer research has come a long way throughout the years. Cancer-fighting medications of today are much more effective than it years of the past. This new era of cancer research has sparked tremendous results by decreasing the mortality and Dr. Clay Siegall is at the forefront of it all. Siegall is the CEO of Seattle Genetics as well as the biotech company’s founder. This man has done it all, and he has worked with many of the biggest names in the industry, including Bristol Myers Squibb, the National Cancer Institute and the National Institute of Health. You’re looking at over 30 years of experience. Seattle Genetics is a worldwide leader in the fight against cancer, and the company’s antibody-drug conjugates have changed the game for the better.
“This biotech-oncology company is looking to make it to the big leagues,” said Siegall. Becoming the next great pharmaceutical company is the main goal, but there has been some ups-and-downs along the way. In the early days, Seattle Genetics struggled as the company was trying to find its footing. After sitting down with a small team of professionals, Siegall decided to bring in an experienced sales team to promote and to close deals. Of course, this experienced team of professionals was a game-changer as it began to close seven-figure deals. As of today, Seattle Genetics specializes in developing and commercializing targeted-cancer therapies. Located in Bothell, Washington, this company has an estimated 900 employees, and it’s one of the largest job producers in the Puget Sound region.
The company’s ADCETRIS medication has generated more than $300 million since it became FDA-approved in 2011. By owning many of the company’s patents and by opening an office in Switzerland, Siegall has put the company on a path to success because it will own its international-marketing rights.